Orbit Genomics leverages its proprietary OrbiSeq technology to revolutionize the field of clinical diagnostics and disease prevention. The company focuses on analyzing repetitive DNA sequences, known as microsatellites, to provide insights into both inherited and acquired disease risks. This innovative approach aids in diagnosing, treating, and ultimately preventing complex diseases such as cancer, heart disease, and diabetes.

Orbit Genomics primarily serves healthcare providers, research institutions, and pharmaceutical companies. Operating within the genomics and clinical diagnostics market, the company employs a B2B (business-to-business) model. Revenue is generated through the sale of diagnostic tests, licensing of their technology, and partnerships with research organizations and pharmaceutical firms.

The company's core technology, OrbiSeq, offers a unique advantage by providing clinically actionable insights that go beyond traditional genetic tests. While conventional tests often measure population risk, OrbiSeq focuses on individual risk, making it a valuable tool for personalized medicine.

Keywords: OrbiSeq, microsatellites, clinical diagnostics, disease prevention, genomics, cancer, heart disease, diabetes, personalized medicine, healthcare providers.